Skip to main content
DLBDolby LaboratoriesSell5.7·$52.64+1.02%
DLB · Concentration risk · 10-K extracted

Dolby Laboratories (DLB) concentration risks

Updated

The most significant concentration Dolby Laboratories discloses is licensing at 93%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Source: Dolby Laboratories’s SEC Form 10-K filed view the filing on SEC EDGAR ↗

At a glance

Disclosed-size breakdown · 2 disclosed concentrations

HIGH2
MEDIUM0
LOW0
Disclosed concentrations

Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).

HIGHBuilt-inProduct / Revenue mix
93%

licensing

10-K Item 1: 'We generated 93% of our revenues in fiscal 2025 by licensing technology, brand, and patents'
SEC 10-K · filed Nov 2025
HIGHOutside partySupplier

sole source suppliers

10-K Item 1: 'we rely on sole source suppliers for certain components used to manufacture our products'
SEC 10-K · filed Nov 2025
TrendMatrix Research · concentration synthesis

What these concentrations mean together

updated 2026-06-24

The company's concentration profile presents two high-share exposures — one in the product and revenue model, one on the supply side — that are structurally independent but both significant by disclosed size. The revenue concentration is the more foundational: the company generated 93% of revenues in fiscal 2025 by licensing technology, brand, and patents — a high share by disclosed size and structural in character. This licensing model is the company's core business architecture, not a transitory channel mix; the concentration reflects decades of investment in audio and imaging technology standards that are now embedded in consumer electronics, cinema, and streaming infrastructure. The tilt toward licensing means results are tied to the volume of licensed device shipments and the durability of intellectual property protection rather than to product sales cycles or customer purchasing patterns. Layered on top is a supply-chain dependency for the small portion of the business that involves manufactured products: the company relies on sole-source suppliers for certain components used in manufacturing, a high-share dependency by disclosed size. This is a dependency by character — an operational disruption at any sole-source supplier could affect product delivery in that segment — though given the licensing-dominant revenue mix, the absolute impact on total revenue from a manufacturing disruption would be limited. Together, the profile is defined primarily by the licensing concentration, which is both the largest revenue source and the most strategically embedded feature of the business model. The sole-source manufacturing dependency is a real but secondary risk. Investors should monitor IP licensing renewal economics and the trajectory of licensed device volumes as the primary variables.

For the engine’s reasoning on DLB’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Industry peers · Specialty Business Services

Peer concentration profile

SymbolNameHIGHMEDIUMLOWTotal
DLBDolby Laboratories2002
ARMKAramark1102
AMTMAmentum Holdings, Inc.1001
ABMABM Industries Incorporated0000
AZZAZZ Inc.0000
CBZCBIZ, Inc.0000

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.

Concentration disclosures are extracted verbatim from SEC 10-K filings; the disclosed-size classification and the synthesis above are engine-derived. Size reflects how large each exposure is against fixed share thresholds (HIGH >50%, MEDIUM 25–50%, LOW <25% or an explicit diversification statement), not a judgment of how dangerous it is, and is not a buy/sell rating, a price target, or a view on the stock. Not a complete list of risk factors — see the full filing.

Home Stocks DLB Concentration risk